Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2017

  • ID: 4446931
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Domainex Ltd
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • MORE
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2017

Summary

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 6 respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chondrosarcoma, Endometrial Cancer, Epithelial Tumor, Follicular Lymphoma, Hematological Tumor, Hepatocellular Carcinoma, Lung Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Rhabdomyosarcoma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, T-Cell Leukemia and Uterine Cancer.

The latest report Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Domainex Ltd
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • MORE
Introduction

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development

Daiichi Sankyo Co Ltd

Domainex Ltd

Epizyme Inc

GlaxoSmithKline Plc

Kainos Medicine Inc

Pfizer Inc

Transgene Biotek Ltd

UNC Health Care

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles

CPI-1205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPI-169 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-3201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBI-2554 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JQEZ-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORS-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EZH2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazemetostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBL-0404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones

Featured News & Press Releases

Dec 12, 2017: Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer

Dec 11, 2017: Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

Dec 10, 2017: Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-3201 at ASH

Nov 01, 2017: Epizyme Provides Update on Tazemetostat

Oct 27, 2017: Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Jul 24, 2017: Epizyme Announces Tazemetostat to be Evaluated in NCI’s Recently Initiated NCI-COG Pediatric MATCH Trial

Jun 21, 2017: Epizyme Announces Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

Jun 14, 2017: Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients

May 18, 2017: Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO

Apr 25, 2017: Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML

Apr 20, 2017: Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO

Nov 28, 2016: Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update

Aug 11, 2016: Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma

Jun 19, 2016: Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Indications, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Daiichi Sankyo Co Ltd, H2

Pipeline by Domainex Ltd, H2

Pipeline by Epizyme Inc, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Kainos Medicine Inc, H2

Pipeline by Pfizer Inc, H2

Pipeline by Transgene Biotek Ltd, H2

Pipeline by UNC Health Care, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Daiichi Sankyo Co Ltd
  • Domainex Ltd
  • Epizyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • Transgene Biotek Ltd
  • UNC Health Care
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll